Cancer-Associated Thrombosis study: REGN7508
Official title REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
ClinicalTrials.gov ID: NCT07410117
What this study is testing
What is REGN7508?
REGN7508 is an investigational injectable medicine being studied for the prevention of cancer‑associated thrombosis (CAT).
Also referred to as cenvacibart.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if REGN7508 can stop cancer‑related blood clots and how it compares to a placebo. It also looks at side effects, drug levels in the blood, and whether the body makes antibodies against the drug.
- Who it's for
- Adults with solid tumors who are receiving or about to start anticancer treatment, or who are recovering from surgery.
- What's involved
- Participants will receive either REGN7508 or a placebo and will have regular visits for blood tests, clot‑risk checks, and monitoring of side effects.
- Time commitment
- The study lasts for the duration of the treatment period, with scheduled visits for drug administration and monitoring.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with...
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study...
You likely can't join if
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for...
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm...
The study team makes the final eligibility decision.
Where it is enrolling
- Hialeah, Florida, United States
- North Miami Beach, Florida, United States
- Boston, Massachusetts, United States
- New York, New York, United States
- Batumi, Adjara, Georgia
- Kutaisi, Imereti, Georgia
- Tbilisi, Georgia
- Tōon, Ehime, Japan
- Ōta, Gunma, Japan
- Akashi, Hyōgo, Japan
- Kita-gun, Kagawa-ken, Japan
- Isehara-Shi, Kanagawa, Japan
- Kyoto, Kyoto, Japan
- Sendai, Miyagi, Japan
- Chuo, Osaka, Japan
- Ina-machi, Saitama, Japan
- Chuo Ku, Tokyo, Japan
- Shinjuku, Tokyo, Japan
- Ube, Yamaguchi, Japan
- Niigata, Japan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Hialeah, Florida, United States; North Miami Beach, Florida, United States; Boston, Massachusetts, United States; New York, New York, United States; Batumi, Adjara, Georgia; Kutaisi, Imereti, Georgia and 14 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.